ZALTENIBART, AN ALTERNATIVE PATHWAY of COMPLEMENT MASP-3 INHIBITOR, IMPROVED HEMATOLOGIC PARAMETERS in PNH PATIENTS with PERSISTENT ANEMIA on RAVULIZUMAB: ADJUNCTIVE and MONOTHERAPY TREATMENT PHASES

Authors
Category Primary study
Conference30th Congress of theEuropean Hematology Association Annual Congress, EHA2025
Year 2025
This article has no abstract
Epistemonikos ID: 82da0d8e016d7bf42e82e88f833e108a661c1902
First added on: Nov 11, 2025